UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Vestal Point Capital LP

Vestal Point Capital LP increased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 307.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,630,000 shares of the company’s stock after purchasing an additional 1,230,000 shares during the quarter. Vestal Point Capital LP owned 0.07% of UroGen Pharma worth $17,360,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of URGN. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma in the 4th quarter valued at about $59,000. Lazard Asset Management LLC acquired a new position in UroGen Pharma in the 4th quarter valued at about $67,000. Aquatic Capital Management LLC acquired a new position in UroGen Pharma in the 4th quarter valued at about $101,000. Oppenheimer & Co. Inc. acquired a new position in UroGen Pharma in the 4th quarter valued at about $126,000. Finally, ProShare Advisors LLC acquired a new position in UroGen Pharma in the 4th quarter valued at about $137,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on URGN. Scotiabank began coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of UroGen Pharma in a research report on Tuesday, May 13th. The Goldman Sachs Group lowered their price objective on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. Finally, Guggenheim reissued a “buy” rating on shares of UroGen Pharma in a research report on Tuesday, April 29th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $32.86.

UroGen Pharma Stock Performance

Shares of UroGen Pharma stock opened at $7.31 on Monday. UroGen Pharma Ltd. has a one year low of $6.46 and a one year high of $20.70. The company has a market cap of $337.04 million, a PE ratio of -2.32 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business has a 50-day simple moving average of $10.59 and a 200-day simple moving average of $10.88.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analysts’ expectations of $22.71 million. On average, equities research analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.